CHC Healthcare Group AI Stock Analysis
CHC Healthcare Group (4164) AI Stock Analysis
CHC Healthcare Group
(TWSE:4164)
CHC Healthcare Group earns a middling score. Fundamentals are mixed: strong 22% revenue growth, a sharp rebound in operating cash flow and a healthier balance sheet with leverage down to 0.71 are offset by significant margin compression, a 4.2% net margin, 2.4% return on equity and thin free cash flow due to heavy capital spending. The technical backdrop is the biggest drag, with the share price below all major moving averages and negative MACD momentum, albeit at deeply oversold levels. Valuation is a partial offset — the 4.55% dividend yield and low beta provide income and stability, though the 21.4 P/E is demanding until profitability recovers. Investors should look for evidence of margin and return-on-capital improvement before the growth story translates into stronger shareholder value.
CHC Healthcare Group (4164) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 4.75B
- Dividend Yield
- 4.52%
- Average Volume (3M)
- 361.47K
- Price to Earnings (P/E)
- 21.5
- Beta (1Y)
- 0.42
- Revenue Growth
- 11.83%
- EPS Growth
- 27.86%
- Country
- TW
- Employees
- 160
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Distribution
CHC Healthcare Group Business Overview & Revenue Model
Company Description
Established in Taipei, Taiwan, in 1977, the CHC Healthcare Group delivers a wide array of healthcare management services both within Taiwan and globally. Its core activities involve the distribution, installation, maintenance, and leasing of medical...
CHC Healthcare Group Financial Statement Overview
Summary
Revenue grew roughly 22% to NT$4.40 billion and operating cash flow rebounded sharply to NT$1.03 billion, while leverage improved to a debt-to-equity ratio of 0.71 as equity rose to NT$7.63 billion. Offsetting this, profitability has deteriorated materially: gross margin fell from about 35% in 2021 to 26%, net margin compressed to 4.2%, and return on equity is a weak 2.4%. Free cash flow turned positive but remains thin at NT$160 million because heavy capital spending consumes most operating cash. The result is a modestly above-average profile driven by growth and cash generation, held back by margin erosion and low returns on a large asset base.
Income Statement
54NeutralBalance Sheet
61PositiveCash Flow
62Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.65B | 4.40B | 3.60B | 3.88B | 2.97B | 2.44B |
| Gross Profit | 1.25B | 1.15B | 759.13M | 1.07B | 902.31M | 849.48M |
| EBITDA | 1.11B | 1.06B | 954.33M | 1.24B | 1.05B | 1.01B |
| Net Income | 225.96M | 186.28M | 168.38M | 418.87M | 356.57M | 381.63M |
Balance Sheet | ||||||
| Total Assets | 16.18B | 15.63B | 14.21B | 13.61B | 12.83B | 12.57B |
| Cash, Cash Equivalents and Short-Term Investments | 1.53B | 1.85B | 1.73B | 2.03B | 1.72B | 1.92B |
| Total Debt | 5.81B | 5.43B | 5.74B | 5.21B | 5.04B | 4.98B |
| Total Liabilities | 8.29B | 7.55B | 7.51B | 6.84B | 6.43B | 6.25B |
| Stockholders Equity | 7.47B | 7.63B | 6.30B | 6.46B | 6.14B | 6.08B |
Cash Flow | ||||||
| Free Cash Flow | -20.56M | 159.96M | -331.72M | 386.92M | -25.97M | 178.70M |
| Operating Cash Flow | 554.20M | 1.03B | 99.37M | 962.59M | 656.66M | 692.79M |
| Investing Cash Flow | -1.19B | -1.60B | -544.86M | -500.46M | -339.98M | -990.35M |
| Financing Cash Flow | 861.00K | 720.88M | 188.24M | -42.05M | -346.45M | 415.06M |
CHC Healthcare Group Peers Comparison
Overall Rating
TW:416670Outperform
TW:412668Neutral- TW:416455Neutral
TW:317642Neutral
TW:473739Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:4166 | 70Outperform | TWD 5.47B | 22.88 | ― | ― | ― | ― |
| TW:4126 | 68Neutral | TWD 5.39B | 12.59 | ― | 6.06% | 1.32% | 7.25% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:4164 | 55Neutral | TWD 4.79B | 21.54 | ― | 4.52% | 11.83% | 27.86% |
| TW:3176 | 42Neutral | TWD 4.62B | -16.84 | ― | ― | 1.11% | -94.39% |
| TW:4737 | 39Underperform | TWD 4.18B | -13.50 | ― | ― | -9.37% | -132.26% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4164 | CHC Healthcare Group | 24.50 | -16.07 | -39.61% | |
| TW:3176 | Medigen Biotechnology Corporation | 33.25 | 3.35 | 11.20% | |
| TW:4126 | Pacific Hospital Supply Co., Ltd. | 74.30 | -9.30 | -11.13% | |
| TW:4166 | Orient Pharma Co., Ltd. | 22.50 | -2.10 | -8.54% | |
| TW:4737 | Bionime Corporation | 55.50 | -6.89 | -11.04% | |
| TW:7902 | Uwell Biopharma Inc. | 25.40 | -2.20 | -7.97% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026